Skip to main content
PLOS One logoLink to PLOS One
. 2023 May 8;18(5):e0285520. doi: 10.1371/journal.pone.0285520

Low genetic heterogeneity of Leishmania major in different geographical regions of Iran

Adel Spotin 1,2,*, Soheila Rouhani 3, Ali Haghighi 3, Parviz Parvizi 4
Editor: Alireza Badirzadeh5
PMCID: PMC10166485  PMID: 37155684

Abstract

To examine the genetic diversity of Leishmania major, 100 Giemsa-stained positive slides were collected from endemic foci of Iran (Northeast, Central, and Southwest provinces) over two consecutive years during 2019–2021. The Leishmania ITS-rDNA gene was amplified and Leishmania sp. was recognized by PCR-RFLP and sequencing. In addition, 178 registered ITS-rDNA sequences from other geographical regions of Iran were retrieved from GenBank, including different host species (human, sandfly and rodent). A total of 40 new haplotypes were discovered using the ITS-rDNA sequence analysis. IR29 (20.6%) and IR34 (61%) were the two most common haplotypes, represented by a star-like feature in the overall population. Analysis of the molecular variance test revealed low genetic diversity of L. major in human cases (Haplotype diversity; 0.341), rodent (Hd; 0.387) and sandfly (Hd; 0.390) sequences. The lowest genetic diversity of L. major was observed in Southwest/Southeast Iran (Hd: 0.104–0.286). The statistically Fst value indicated that L. major is not genetically differentiated between geographic regions of Iran, except for the Northeast-Southwest (Fst: 0.29055) and Central-Southwest (Fst: 0.30294) population pairs. The current study as the first investigation discloses new perspectives for further evaluation in the identification local transmission paradigms and initiating effective prevention strategies.

1. Introduction

Cutaneous leishmaniasis (CL) is one of the neglected tropical diseases that is mainly spread in Iran by the causative agents of Leishmania major and Leishmania tropica [1, 2]. CL is prevalent in more than half of the Iranian provinces with a prevalence of 1.8% to 37.9% and an annual incidence of 26,630 cases/year [3, 4].

The spectrum of genetic (haplotype) variability in L. major is presented as one of the most controversial issues [1, 2, 5, 6]. The genetic heterogeneity of Leishmania species may result in the emergence of new species/strains/haplotypes and ultimately the creation of drug-resistant mutants [5, 6]. With regard to treatment failure, the identification of heterogeneity traits of Leishmania spp. and the emergence of resistant drug mutations should be addressed by policymakers.

Several mitochondrial and nuclear DNA markers, including microsatellites, ribosomal internal transcribed spacer regions (ITS-rDNA), cytochrome c, 18S-rRNA, HSP-70, the gp63 gene locus, and minicircles of kinetoplast DNA were used to assess the genetic diversity of the Leishmania parasite [1, 712]. The ITS-rDNA is a useful and informative phylogenetic marker as it has sequences with different rates of evolutionary variability [5, 13]. A number of molecular assays have been employed to identify genetic polymorphism between inter-and intra-Leishmania species [14, 15]. These include multilocus microsatellite typing (MLMT), random amplification of polymorphic DNA (RAPD), restriction fragment length polymorphism (RFLP), multilocus enzyme electrophoresis (MLEE), multilocus sequence typing (MLST) and sequencing.

Several Iranian researchers have performed their molecular experiments on L. major genotyping in different host species (human, sandfly and rodent) and their results have shown that the new haplotypes circulate sympatrically in endemic regions of the country [1619]. However, according to our literature review, there is no comparative study on the genetic diversity of L. major among different endemic foci of Iran.

Knowledge of the genetic characteristics of L. major in adjacent regions may provide the basis for conducting future epidemiological studies to implement control strategies. The aim of this study was to assess the genetic diversity and gene migration of L. major using ITS-rDNA nucleotide sequences derived from human, sandfly and rodent in endemic regions of Iran.

2. Materials and methods

2.1. Ethics statement and sample collection

All research involving human participants have been obtained in conformity with informed consent, privacy and confidentiality of patients who were sampled and analyzed anonymously during study. The majorities of the people were in the edge of Iran border and therefore could not able to get written consent one by one. Instead, the oral consent was obtained with the help of central public health authority as both mutual acquaintance and interpreter of the indigenous peoples. All experiments on the humans were performed according to the guidelines of the Ethical Board of Pasteur Institute of Iran.

One hundred positive microscopic slides from wet/dry lesions of confirmed CL patients were collected from endemic geographical regions of Iran (Southwest, Khuzestan Province; n: 40, Northeast, Golestan Province; n: 30 and Central; Isfahan Province; n: 30) from August 2019 to February 2021. In this study, the collected samples from indigenous cases were included and the imported cases from neighboring countries were excluded.

The positive slides were graded to rank leishman bodies’ density from +1 to +6. In addition, in order to compare the analyzed sequences of the present study with five regions of Iran, 178 sequences of ITS-rDNA L. major including Southwest (Khuzestan, Ilam and Fars provinces), Central (Isfahan and Kashan provinces), North (Tehran Province), Southeast (Kerman), North-Central (Semnan), West (Lorestan and Kermanshah provinces) and Northeast (Golestan, Turkmen Sahra), Khorasan (Birjand, Esfarayen, Mashhad, Jajarm and Garmeh) populations were retrieved from the GenBank database for FASTA during 2008–2020.

2.2. DNA extraction, PCR amplification and PCR-RFLP for ITS-rDNA

DNA extraction of parasites was performed from Giemsa-stained positive slides (DNG Plus Kit, Iran) [20]. Single-round PCR was used to detect Leishmania sp. by amplifying ITS-rDNA about 480 bp. The details of PCR protocol and employed primers (ITS1F and ITS2R4) were the same as previously reported [1, 9, 17]. To digest the PCR amplicons in RFLP, the endonuclease reaction of ITS-rDNA was performed in a volume of 30μL containing, 2μL of 10x buffer, 2μL of BsuRI (HaeIII) (cut site GG↓CC), 10μL of amplicon and 16μL of distilled water for 4 h at 37C. The digested fragments were analyzed using electrophoresis on 1.5% agarose gel containing safe stain and ladder of 100 bp.

2.3. DNA sequencing, data extraction and bioinformatic analysis of ITS-rDNA

Forty PCR products were successfully sequenced using the ITS primers, ITS1F and ITS2R4 (Codon Company, Iran). Sequences were trimmed and edited in consensus positions compared to regional sequences using Sequencher v.5.4.6 software. Furthermore, 178 registered ITS-rDNA nucleotide sequences of L. major from other geographic populations of Iran including different host species (human, sandfly and rodent) were downloaded from GenBank. The analysis of molecular variance (AMOVA) was performed by DnaSP software to determine the genetic diversity indices (number of haplotypes (Hn); nucleotide diversity (Nd); haplotype diversity (Hd), neutrality indices (Tajima’s D and Fu’s Fs tests) [21]. The pairwise fixation index (Fst: F-statistics) and number of migration (Nm) were obtained to assess the gene migration of L. major between different geographical regions of Iran. To ascertain the genealogical relationships of intra-species diversity of L. major, a haplotype network was drawn by PopART software determined by the Median-Joining model [22]. To confirm taxonomic status of the L. major, a phylogenetic tree was constructed using the program Splits Tree v.4.0 based on the Neighbor Net method and Median-Joining analysis. Distance scale was 0.01 indicating the number of base substitutions per site. Also Trypanosoma brucei (Accession number; JN673390) was considered as an outgroup branch.

3. Results

3.1. Identification of Leishmania sp. using PCR-RFLP

The clinical presentations of wet/dry lesions were classified into classic (volcanic form) and non-classic (psoriasiform, herpetiform, hyperkeratotic, eczematoid, zosteriform and erythematous papulonodules signs). The ITS-rDNA gene (480 bp) was amplified from all 100-CL stained slides. Based on the PCR-RFLP assay, all Leishmania PCR products were digested by BsuRI (HaeIII) and then two fragments of 140 bp and 340 bp were definitely assigned to L. major. To confirm the PCR-RFLP findings, 40 L. major amplicons were successfully sequenced, trimmed and edited to construct the phylogenetic tree.

3.2. Determination of genetic diversity and genetic differentiation between L. major

The edited sequences (n: 40) were compared with sequences obtained (n: 178) from the GenBank database. Ten sequences (including new haplotypes) were submitted to the GenBank database, and accession numbers were presented in S1 Table. A total of 40 new haplotypes were identified based on sequence analysis of the ITS-rDNA gene (S1 Table). According to AMOVA test, low genetic heterogeneity of L. major was found in Southwest (Hd: 0.104, Hn: 5), Southeast (Hd: 0.286, Hn: 2), Central (Hd: 0.419, Hn: 10), in the west (Hd: 0.334, Hn: 4), Northeast (Hd: 0.429, Hn: 17) and North-Central Iran (Hd: 0.400, Hn: 2) (Table 1).

Table 1. Diver sity and neutrality indices of L. major using ITS-rDNA sequences in various geographical regions of Iran.


Region
Province/cities (n)
Diversity indices Neutrality indices
N Hn Hd± SD Polymorphic sites Nd (π) K Tajima’s D* Fu’s Fs statistic**
Central Iran Isfahan (16), Kashan (14) (Aran Bidgol) 30 10 0.419±0.080 17 0.01005 2.724 -1.49695 -9.012
Southwest Iran Fars (1), Ilam (37), Khuzestan(10) 48 5 0.104±0.067 31 0.00894 2.083 -2.56931 4.546
Northeast Iran Khorasan (Birjand; 25, Esfarayen; 31, Mashhad; 13, Jajarm; 5, Garmeh; 3), Golestan (37; Turkmen sahra) 114 17 0.429± 0.059 41 0.00901 2.459 -2.27541 -9.662
Southeast Iran Kerman (n; 7, Bam, Jiroft and Shahdad) 7 2 0.286± 0.196 4 0.00351 1.143 -1.43414 2.047
West Iran Lorestan (8), Kermanshah (6; Ghasre shirin) 14 4 0.334±0.045 29 0.02279 6.154 -1.75475 -0.796
North central Iran Semnan (Damghan; 5) 5 2 0.400± 0.175 1 0.00202 0.600 1.22474 0.626
Total 218 40

N: number of isolates; Hn: number of haplotypes; Hd: haplotype diversity; Nd: nucleotide diversity; K: Average number of nucleotide differences.*Significant, P < 0.01**Significant, P < 0.02

Based on host species, low genetic (haplotype) diversity of L. major was observed in reservoir rodents (Rhombomys opimus and Meriones libycus, Hd; 0.387, Hn: 10) and sandflies (Phlebotomus papatasi/Phlebotomus caucasicus, Hd; 0.390, Hn: 7) compared to human CL cases (Hd; 0.441, Hn: 23) (Table 2). The highest nucleotide diversity was found in Central Iran (Nd: 0.01005) particularly in reservoir rodents (Nd: 0.01164) (Tables 1 and 2). Neutrality indices of ITS-rDNA showed negative values (-2.27541 for Tajima’s D to -9.662 for Fu’s Fs statistic) in Northeast, West and Central populations which indicating a deviation from neutrality (Table 1). Within 480 bp consensus position of ITS-rDNA, 48 point mutations were identified. 24 of these were parsimony-informative sites and 24 of these were singleton variable sites. The statistically Fst value showed that L. major is not genetically differentiated between geographic regions of Iran (Fst: 0.01649 to 0.07820) except Northeast-Southwest (Fst: 0.29055, Nm: 0.61) and Central-Southwest (Fst: 0.30294, Nm: 0.58) population pairs (Table 3).

Table 2. Diversity and neutrality indices of L. major in different host species (human, sandfly and rodent) using ITS-rDNA sequences in various geographical regions of Iran.


Parasite
Host-vector
Diversity indices Neutrality indices
N Hn Hd± SD Nd (π) Polymorphic site K Tajima’s D* Fu’s Fs statistic**
Leishmania major Vector (Sandfly) Phlebotomus papatasi/ Phlebotomus caucasicus 25 7 0.390±0.079 0.00565 8 1.600 -0.77730 -1.466
Reservoir (Vertebrate hosts) Human 168 23 0.441 ± 0.030 0.00426 23 1.205 -2.03615 -29.979
Rodents: Rhombomys opimus and Meriones libycus 25 10 0.387± 0.105 0.01164 29 3.923 -1.95708 -2.662
Total 218 40

* Significant, P<0.01

**Significant, P <0.02.

N: number of isolates; Hn: number of haplotypes; Hd: haplotype diversity; Nd: nucleotide diversity; K: Average number of nucleotide differences.

Table 3. Pairwise fixation index (Fst) for L. major isolates originating from five regions of Iran using nucleotide sequence data of ITS-rDNA.

Region
Province (cities)
Populations
Central Iran Southwest Iran West Iran Northeast Iran
Central Iran Isfahan and Kashan (Aran Bidgol) Nm: 0.58 Nm: 6.52 Nm: 14.91
Southwest Iran Fars, Ilam and Khuzestan 0.30294 - Nm: 2.95 Nm: 0.61
West Iran Lorestan, Kermanshah (Ghasre shirin) 0.03692 0.07820 - Nm: 2.50
Northeast Iran Khorasan (Birjand, Esfarayen, Mashhad, Jajarm and Garmeh), Golestan (Turkmen sahra) 0.01649 0.29055 0.09078 -

3.3. Phylogenetic tree and haplotype network of ITS-rDNA

Neighbor Net tree generated by ITS-rDNA sequences demonstrated that L. major identified

(Accession nos; OP811334, OP811489, OP811525, OP829807-OP829812) assigned into L. major complex (Fig 1). The identified haplotypes (IR1-1R40) based on their different host species are presented in Fig 2. A total of 7, 10 and 23 haplotypes of L. major were detected in the sandfly, rodent and human, respectively in the different CL foci of Iran (Fig 2 and Table 2). IR29 (20.6%) and IR34 (61%) were the two most common haplotypes in the whole population, represented by a star-like feature in the overall population.

Fig 1. Neighbor-Net graph drawn by Leishmania spp. by using the Splits Tree 4.0 program.

Fig 1

The identified isolates of L. major in this study marked by an asterisk (*). Trypanosoma brucei (Accession no: JN673390) was considered as out-group branch. The distance scale was estimated 0.01.

Fig 2. ITS-rDNA haplotype network in L. major from different host species (human, sandfly and rodent) in various geographical foci of Iran.

Fig 2

Submitted sequences (n: 10) in this study were considered as common haplotype L. m1 (OP811334*). The red circles are relative to the frequency of each haplotype. Each line between haplotypes indicate single mutational step.

Occurrence of haplotypes of IR28 (Accession no: KF899848) and IR31 (Accession no: KP773410) between common haplotypes of IR29 and IR34 suggests that human-derived L. major may circulate between geographic regions of Iran (Fig 2).

4. Discussion

Knowledge of L. major genetic diversity of is essential to design epidemiological studies to implement monitoring, surveillance and control programs [5, 6]. This study analyzed the nucleotide sequence data on the heterogeneous population structure of L. major originating from sandfly, rodent and human hosts in Iran where different ecological conditions occur in widely separated regions.

In this study, the ITS-rDNA marker was used to detect the evolutionary relationship of L. major, as this DNA barcode marker can depict a reliable picture of the various phylogenetic subdivisions within this genus [13].

Based on current findings, micro-heterogeneity of L. major observed in reservoir rodents (R. opimus and M. libycus), sandfly vectors (Ph. papatasi/Ph. caucasicus) and human CL cases. This outcome indicates that rodents, sandflies, and human hosts are unlikely to exert a selective pressure on L. major and emphasizes the geographic/ecologic dependence of the low genetic heterogeneity in Iran. On the other hand, low genetic diversity of L. major in human, rodent and sandfly sequences can be explained by the genomic features of ITS-rDNA. In fact, the GC content of L. major (59.7%) is generally higher than that of L. tropica, so the stability of the triple hydrogen bonds of the GC pair and the stacking interaction are subjected to slippage [23, 24].

In a related study, low genetic heterogeneity of L. major isolates collected from patients and rodents was identified by MLMT technique in emergent foci of zoonotic cutaneous leishmaniasis in Tunisia [25, 26].

However, Tashakori et al., (2011) have shown three distinct genetic clusters of L. major (n: 26 isolates) using MLMT in Iran and they stated that significant genetic diversity of L. major is related to the existence of different populations of Ph. papatasi and/or differences in the abundance of reservoir hosts in different regions of Iran [27].

Some evidence suggests that the level of genetic diversity in the Leishmania parasite depends on the effective population size and is higher in small populations [5]. Furthermore, environmental alterations and biotic interactions among five regions of Iran can exert strong selective pressures on different life-history aspects and hence influence their degree of genetic diversity in Leishmania parasite [5]. However, other authors have reported a decreasing degrees of genetic diversity among the following Leishmania spp.; L. tropica> L. aethiopica> L. major> L. donovani [28].

In this study, a variety of clinical manifestations (classical and non-classical forms) of L. major were observed in human lesions, however no significant genetic diversity (Hd; 0.541) was found among ITS-rDNA sequences of L. major in Khuzestan, Southwest Iran. These findings attenuate relationship between phenotypic and genotypic traits of CL in L. major patients, possibly demonstrating that genetic heterogeneity may not definitely influence the formation of various clinical manifestations.

The negative neutrality indices for the L. major population indicate evidence of some likely mechanisms including the neutral mutation model, population size equilibrium and purifying selection [29].

The significant Fst values (0.29055 to 0.30294) of ITS-rDNA sequences showed that L. major Northeast-Southwest and Central-Southwest populations were genetically differentiated. It could be postulated that no gene migration of L. major taken place between local isolates of the mentioned regions. This also indicates that the diversity of the L. major population was unlikely to be affected by the bottleneck effect.

Furthermore, the occurrence of distinct genetic structure of L. major between mentioned regions indicates that this protozoan may have been sustained by indigenous human, rodents and sandflies during the era. On the other hand, low values of Fst (0.01649 to 0.07820) showed that L. major West-Central, Central-Northeast, West-Southwest populations were not genetically differentiated, indicating a gene migration of L. major has probably occurred between mentioned population pairs.

The emergence of haplotypes of IR28 (human isolate) and IR31 (human isolate) between common haplotypes of IR29 and IR34 shows that here is dawn of L. major migration as a result of transmission of haplotypes from one population to another population through ecological changes and/or host mobility.

Charyyeva et al., (2021) demonstrated that L. tropica isolated from Syrian and Turkish patients using ITS1 sequences exhibits a complex phylo-geographic pattern, with some haplotypes being widespread across the Turkey and Syria [30].

One of the limitations of the current study was that the L. major sequences obtained from sandflies and rodents were partially small, in order to infer the extensive genetic diversity on a large scale.

In conclusion, the present study as the first investigation strengthens our knowledge of local transmission paradigms and the genetic data of L. major in different geographical regions of Iran. Moreover low genetic heterogeneity of L. major in human, rodent and sandfly hosts should be highlighted as a treatment target for the emergence of probable drug-resistant mutants, particularly in clinical Leishmania strains. Further research is needed to develop next-generation sequencing of Leishmania sp. through the use of informative markers in larger areas of Iran and surrounding countries to assess the potential evolutionary scenario.

Supporting information

S1 Table. Identified haplotypes of L. major based on ITS-rDNA sequences in various geographical foci of Iran.

(DOCX)

Acknowledgments

The collections of microscopic slides were made possible by the assistance of the Centre of Health Services Khuzeastan and Golestan. The authors thank Mehdi Baghban for helping with the field work and Elnaz AlaeeNovin for helping in Molecular Systematics Laboratory.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This study was financially supported by Iran National Science Foundation: INSF, 99014249, Dr. Adel Spotin.

References

  • 1.Spotin A, Rouhani S, Parvizi P (2014) The associations of Leishmania major and Leishmania tropica aspects by focusing their morphological and molecular features on clinical appearances in Khuzestan province, Iran. BioMed Res Int 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mirzapour A, Spotin A, Behniafar H, Azizi H, Maleki B, et al. (2019) Intra-species diversity of Leishmania major and L. tropica from clinical isolates of cutaneous leishmaniasis in southwest iran inferred by ITS1-rDNA. Iran J Public Health 48: 893. [PMC free article] [PubMed] [Google Scholar]
  • 3.Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671. doi: 10.1371/journal.pone.0035671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Badirzadeh A, Asadgol Z, Spotin A, Mokhayeri Y, Shirzadi M, et al. (2015) The burden of leishmaniasis in Iran: findings from the global burden of disease from 1990 to 2010; Asian Pac J Trop Dis 7(9):513–518. [Google Scholar]
  • 5.Banuls A-L, Hide M, Prugnolle F (2007) Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv Parasitol 64: 1–458. [DOI] [PubMed] [Google Scholar]
  • 6.Santi AMM, Murta SMF (2022) Impact of Genetic Diversity and Genome Plasticity of Leishmania spp. in Treatment and the Search for Novel Chemotherapeutic Targets. Front Cell Infect Microbiol 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yatawara L, Le TH, Wickramasinghe S, Agatsuma T (2008) Maxicircle (mitochondrial) genome sequence (partial) of Leishmania major: gene content, arrangement and composition compared with Leishmania tarentolae. Gene 424: 80–86. [DOI] [PubMed] [Google Scholar]
  • 8.Yurchenko V, Kolesnikov AA, Lukes J (2000) Phylogenetic analysis of Trypanosomatina (Protozoa: Kinetoplastida) based on minicircle conserved regions. Folia Parasitol 47: 1–5. doi: 10.14411/fp.2000.001 [DOI] [PubMed] [Google Scholar]
  • 9.Parvizi P, Ready P (2008) Nested PCRs and sequencing of nuclear ITS‐rDNA fragments detect three Leishmania species of gerbils in sandflies from Iranian foci of zoonotic cutaneous leishmaniasis. Trop Med Int Health 13: 1159–1171. [DOI] [PubMed] [Google Scholar]
  • 10.Montalvo A, Fraga J, Monzote L, Montano I, De Doncker S, et al. (2010) Heat-shock protein 70 PCR-RFLP: a universal simple tool for Leishmania species discrimination in the New and Old World. Parasitology 137: 1159–1168. [DOI] [PubMed] [Google Scholar]
  • 11.Bulle B, Millon L, Bart J-M, Gállego M, Gambarelli F, et al. (2002) Practical approach for typing strains of Leishmania infantum by microsatellite analysis. J Clin Microbiol 40: 3391–3397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Victoir K, Banuls A, Arevalo J, Llanos-Cuentas A, Hamers R, et al. (1998) The gp63 gene locus, a target for genetic characterization of Leishmania belonging to subgenus Viannia. Parasitology 117: 1–13. [PubMed] [Google Scholar]
  • 13.Hillis DM, Moritz C, Porter CA, Baker RJ (1991) Evidence for biased gene conversion in concerted evolution of ribosomal DNA. Science 251: 308–310. doi: 10.1126/science.1987647 [DOI] [PubMed] [Google Scholar]
  • 14.Schönian G, Kuhls K, Mauricio I (2011) Molecular approaches for a better understanding of the epidemiology and population genetics of Leishmania. Parasitology 138: 405–425. [DOI] [PubMed] [Google Scholar]
  • 15.Spotin A, Rouhani S, Ghaemmaghami P, Haghighi A, Zolfaghari MR, et al. (2015) Different morphologies of Leishmania major amastigotes with no molecular diversity in a neglected endemic area of zoonotic cutaneous leishmaniasis in Iran. Iran Biomed J 19: 149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Oryan A, Shirian S, Tabandeh M-R, Hatam G-R, Randau G, et al. (2013) Genetic diversity of Leishmania major strains isolated from different clinical forms of cutaneous leishmaniasis in southern Iran based on minicircle kDNA. Infect Genet Evol 19: 226–231. [DOI] [PubMed] [Google Scholar]
  • 17.Sharbatkhori M, Spotin A, Taherkhani H, Roshanghalb M, Parvizi P (2014) Molecular variation in Leishmania parasites from sandflies species of a zoonotic cutaneous leishmaniasis in northeast of Iran. J Vector Borne Dis 51: 16–21. [PubMed] [Google Scholar]
  • 18.Mirzaei A, Rouhani S, Taherkhani H, Farahmand M, Kazemi B, et al. (2011) Isolation and detection of Leishmania species among naturally infected Rhombomis opimus, a reservoir host of zoonotic cutaneous leishmaniasis in Turkemen Sahara, North East of Iran. Exp Parasitol 129: 375–380. doi: 10.1016/j.exppara.2011.08.020 [DOI] [PubMed] [Google Scholar]
  • 19.Hajjaran H, Mohebali M, Mamishi S, Vasigheh F, Oshaghi MA, et al. (2013) Molecular identification and polymorphism determination of cutaneous and visceral leishmaniasis agents isolated from human and animal hosts in Iran. BioMed Res Int 2013. doi: 10.1155/2013/789326 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Parsaei M, Raeisi A, Spotin A, Shahbazi A, Mahami-Oskouei M, et al. (2018) Molecular evaluation of pvdhfr and pvmdr-1 mutants in Plasmodium vivax isolates after treatment with sulfadoxine/pyrimethamine and chloroquine in Iran during 2001–2016. Infect Genet Evol 64: 70–75. [DOI] [PubMed] [Google Scholar]
  • 21.Rozas J, Sánchez-DelBarrio JC, Messeguer X, Rozas R (2003) DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19: 2496–2497. doi: 10.1093/bioinformatics/btg359 [DOI] [PubMed] [Google Scholar]
  • 22.Bandelt H-J, Forster P, Röhl A (1999) Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 16: 37–48. doi: 10.1093/oxfordjournals.molbev.a026036 [DOI] [PubMed] [Google Scholar]
  • 23.Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436–442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schönian G, Schnur L, El Fari M, Oskam L, Kolesnikov AA, et al. (2001) Genetic heterogeneity in the species Leishmania tropica revealed by different PCR-based methods. Trans R Soc Trop Med Hyg 95: 217–224. [DOI] [PubMed] [Google Scholar]
  • 25.Attia H, Sghaier RM, Gelanew T, Bali A, Schweynoch C, et al. (2016) Genetic micro-heterogeneity of Leishmania major in emerging foci of zoonotic cutaneous leishmaniasis in Tunisia. Infect Genet Evol 43: 179–185. [DOI] [PubMed] [Google Scholar]
  • 26.Ghawar W, Attia H, Bettaieb J, Yazidi R, Laouini D, et al. (2014) Genotype profile of Leishmania major strains isolated from tunisian rodent reservoir hosts revealed by multilocus microsatellite typing. PLoS One 9: e107043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mahnaz T, Al-Jawabreh A, Kuhls K, Schönian G (2011) Multilocus microsatellite typing shows three different genetic clusters of Leishmania major in Iran. Microbes Infect 13: 937–942. [DOI] [PubMed] [Google Scholar]
  • 28.Schönian G, El Fari M, Lewin S, Schweynoch C, Presber W (2001) Molecular epidemiology and population genetics in Leishmania. Med Microbiol Immunol 190: 61–63. [DOI] [PubMed] [Google Scholar]
  • 29.Huyse T, Poulin R, Theron A (2005) Speciation in parasites: a population genetics approach. Trends Parasitol 21: 469–475. doi: 10.1016/j.pt.2005.08.009 [DOI] [PubMed] [Google Scholar]
  • 30.Charyyeva A, Çetinkaya Ü, Özkan B, Şahin S, Yaprak N, et al. (2021) Genetic diversity of Leishmania tropica: Unexpectedly complex distribution pattern. Acta Trop 218: 105888. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Alireza Badirzadeh

27 Feb 2023

PONE-D-23-00609Low genetic heterogeneity of Leishmania major in various geographical regions of IranPLOS ONE

Dear Dr. Spotin,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 13 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alireza Badirzadeh

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

6. We note that Figure 1 in your submission contain [map/satellite] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (a) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (b) remove the figures from your submission:

a. You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

b. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors investigated the genetic diversity of Leishmania major, 100 positive stained slides were collected from endemic foci of Iran (Northeastern, Central, and Southwestern provinces) over two consecutive years during 2019-2021. In general this is well-written manuscript, important for the field and for the region. I suggest to cut Introduction and to focus only on the topic, also please be focused in Discussion. Methodology is well written. English should be revised by English speaker.

Reviewer #2: The manuscript presents a good concept; however, some points are not clear to the reviewer which are summarized below:

In Abstract

-In line 15: “100 positive stained slides” please determine, Giemsa or Wright stained slides?

-In line 24, please correct the spelling of "Haplotype". And check the spelling of all of the text.

-Please “PCR-RFLP” added to the Keywords.

In introduction

-Considering the low genetic diversity of L. major was observed in other studies in Iran, please explain the novelty and necessity of conducting this study.

-In lines 49-53: Despite the existence of a number of molecular assays for identifying genetic polymorphism, why did you choose the "RFLP" method among them?

Despite the existence of a number of methods, why did you use the "L" method among them?

In Materials and methods

-According to the wideness of the selected geographical areas, the number of 100 slides is not suitable. Was there a reason for not providing more slides?

-What inclusion and exclusion criteria are considered in the selection of patients? For example, are immigrants or imported cases considered?

-In lines 65 and 86: Please write the number in the form of a letter at the beginning of the sentence, for example, "one hundred".

In discussion

-In line 148: the full form of ITS-rDNA has already been mentioned, please just write the abbreviation form.

-Please mention the limitations of this research in the discussion section.

Reviewer #3: The manuscript entitled "Low genetic heterogeneity of Leishmania major in various geographical regions of Iran" describes the diversity of L. major isolates and its implication on the epidemiology of zoonotic cutaneous leishmaniasis in Iran. However, several points must be addressed. Thus, I recommend that this manuscript should be published only after considering these major following changes.

Specific Comments

- All the Tables can go to supplements.

- Please explain why only 40 amplicons (out of 100) were sequenced?

- Please put your research in the context of similar studies in other Leishmania spp. from the same region.

- The authors should discuss further the results obtained by this method used in this study compared to the findings of other studies performed by using MLMT or NGS reporting contrasting results.

- The authors referred to one study instead to reporting the results of most studies performed on L. major.

- The authors should discuss the findings of other studies performed in Turkey and Syria (entitled: Genetic diversity of Leishmania tropica: Unexpectedly complex distribution pattern; F.e. doi:10.1016/j.actatropica.2021.105888.) by comparison with the results of this study.

- - Resolution of figures must be improved.

- Line 68: The location of Fig 2 don’t support in the text.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Aleksandra Barac

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 May 8;18(5):e0285520. doi: 10.1371/journal.pone.0285520.r002

Author response to Decision Letter 0


27 Mar 2023

To: Plos One

Dear Dr. Alireza Badirzadeh

This is my FIRST revision of manuscript

Ms. Ref. No.: PONE-D-23-00609

Title: “Low genetic heterogeneity of Leishmania major in various geographical regions of Iran”

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: Authors investigated the genetic diversity of Leishmania major, 100 positive stained slides were collected from endemic foci of Iran (Northeastern, Central, and Southwestern provinces) over two consecutive years during 2019-2021. In general this is well-written manuscript, important for the field and for the region. I suggest to cut Introduction and to focus only on the topic, also please be focused in Discussion. Methodology is well written. English should be revised by English speaker.

Response: Thank you. Discussion was revised and English was polished entire MS.

Reviewer #2: The manuscript presents a good concept; however, some points are not clear to the reviewer which are summarized below:

In Abstract

-In line 15: “100 positive stained slides” please determine, Giemsa or Wright stained slides?

Response: The “100 Giemsa stained positive” was highlighted in line15.

-In line 24, please correct the spelling of "Haplotype". And check the spelling of all of the text.

Response: It was done and highlighted in line 24.

-Please “PCR-RFLP” added to the Keywords. Response: It was done and highlighted

In introduction

-Considering the low genetic diversity of L. major was observed in other studies in Iran, please explain the novelty and necessity of conducting this study.

Response: In this study, for the first time, haplotype distribution and gene migration of Leishmania major were assessed among various sources of human, rodent and sandfly in different geographical regions of Iran which can depict a real picture of epidemiology of parasite.

-In lines 49-53: Despite the existence of a number of molecular assays for identifying genetic polymorphism, why did you choose the "RFLP" method among them? Response: Among the known molecular methods, the PCR-RFLP for ITS-rDNA using BsuRI (HaeIII) enzyme has widely used because of the ease in differentiating Leishmania major, L. tropica and L. infantum.

In Materials and methods

-According to the wideness of the selected geographical areas, the number of 100 slides is not suitable. Was there a reason for not providing more slides?

Response: In this study, we were able to collect 100 positive slides during 2019-2021. To solve this gap, the sequences recorded (GenBank) from Iran was used to compare genomic analyzes.

-What inclusion and exclusion criteria are considered in the selection of patients? For example, are immigrants or imported cases considered?

Response: In this study, the collected samples from indigenous cases were included and the imported cases from neighboring countries were excluded (Lines 67-68).

-In lines 65 and 86: Please write the number in the form of a letter at the beginning of the sentence, for example, "one hundred". Response: Thank you. It was done and highlighted.

In discussion

-In line 148: the full form of ITS-rDNA has already been mentioned, please just write the abbreviation form. Response: It was done and highlighted.

-Please mention the limitations of this research in the discussion section. Response: It was mentioned in line 193.

Reviewer #3: The manuscript entitled "Low genetic heterogeneity of Leishmania major in various geographical regions of Iran" describes the diversity of L. major isolates and its implication on the epidemiology of zoonotic cutaneous leishmaniasis in Iran. However, several points must be addressed. Thus, I recommend that this manuscript should be published only after considering these major following changes.

Specific Comments

- All the Tables can go to supplements. Response: Due to the fact that tables 2 to 4 are directly related to the explanations of the results section of the article, therefore table 1 was considered as supplementary file.

- Please explain why only 40 amplicons (out of 100) were sequenced? Response: In this study, only 40 samples were successfully sequenced due to limited financial resources, bad sequencing and permanent non-specific bands.

- Please put your research in the context of similar studies in other Leishmania spp. from the same region. Response: It was done in conclusion and highlighted.

- The authors should discuss further the results obtained by this method used in this study compared to the findings of other studies performed by using MLMT or NGS reporting contrasting results. Response: It was done (lines 161-163, 164-167).

- The authors referred to one study instead to reporting the results of most studies performed on L. major. Response: It was discussed and highlighted in discussion.

- The authors should discuss the findings of other studies performed in Turkey and Syria (entitled: Genetic diversity of Leishmania tropica: Unexpectedly complex distribution pattern; F.e. doi:10.1016/j.actatropica.2021.105888.) by comparison with the results of this study.

Response: It was discussed and highlighted in lines 194-196.

- - Resolution of figures must be improved. Response: The resolution of Figs was improved to 300 dpi.

- Line 68: The location of Fig 2 don’t support in the text. Response: Thank you. It was corrected.

Kind Regards

Adel Spotin, Ph.D.

*Corresponding author: Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran, Email: Adelespotin@gmail.com, Spotina@tbzmed.ac.ir

Attachment

Submitted filename: R1 point-by-point response to reviewers 11 March 2023.docx

Decision Letter 1

Alireza Badirzadeh

26 Apr 2023

Low genetic heterogeneity of Leishmania major in different geographical regions of Iran

PONE-D-23-00609R1

Dear Dr. Adel Spotin,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alireza Badirzadeh

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: The authors carried out all corrections in the manuscript. It seems the manuscript is appropriate for publication in this journal.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

**********

Acceptance letter

Alireza Badirzadeh

28 Apr 2023

PONE-D-23-00609R1

Low genetic heterogeneity of Leishmania major in different geographical regions of Iran

Dear Dr. Spotin:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alireza Badirzadeh

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Identified haplotypes of L. major based on ITS-rDNA sequences in various geographical foci of Iran.

    (DOCX)

    Attachment

    Submitted filename: R1 point-by-point response to reviewers 11 March 2023.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES